Erik Boot

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2678636/publications.pdf

Version: 2024-02-01

58 papers	2,592 citations	236612 25 h-index	197535 49 g-index
62 all docs	62 docs citations	62 times ranked	3409 citing authors

#	Article	IF	Citations
1	Psychiatric Disorders From Childhood to Adulthood in 22q11.2 Deletion Syndrome: Results From the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome. American Journal of Psychiatry, 2014, 171, 627-639.	4.0	645
2	Practical guidelines for managing adults with 22q11.2 deletion syndrome. Genetics in Medicine, 2015, 17, 599-609.	1.1	222
3	Cognitive Decline Preceding the Onset of Psychosis in Patients With 22q11.2 Deletion Syndrome. JAMA Psychiatry, 2015, 72, 377.	6.0	196
4	Lower striatal dopamine D2/3 receptor availability in obese compared with non-obese subjects. EJNMMI Research, 2011, 1, 37.	1.1	149
5	Genetic contributors to risk of schizophrenia in the presence of a 22q11.2 deletion. Molecular Psychiatry, 2021, 26, 4496-4510.	4.1	87
6	Update on the 22q11.2 deletion syndrome and its relevance to schizophrenia. Current Opinion in Psychiatry, 2017, 30, 191-196.	3.1	77
7	Rare Genome-Wide Copy Number Variation and Expression of Schizophrenia in 22q11.2 Deletion Syndrome. American Journal of Psychiatry, 2017, 174, 1054-1063.	4.0	77
8	Neurobiological perspective of 22q11.2 deletion syndrome. Lancet Psychiatry,the, 2019, 6, 951-960.	3.7	70
9	Obesity in adults with 22q11.2 deletion syndrome. Genetics in Medicine, 2017, 19, 204-208.	1.1	60
10	Disrupted Dopaminergic Neurotransmission in 22q11 Deletion Syndrome. Neuropsychopharmacology, 2008, 33, 1252-1258.	2.8	56
11	Enhanced Maternal Origin of the 22q11.2 Deletion in Velocardiofacial and DiGeorge Syndromes. American Journal of Human Genetics, 2013, 92, 439-447.	2.6	53
12	Movement disorders and other motor abnormalities in adults with 22q11.2 deletion syndrome. American Journal of Medical Genetics, Part A, 2015, 167, 639-645.	0.7	49
13	Internet Safety Issues for Adolescents and Adults with Intellectual Disabilities. Journal of Applied Research in Intellectual Disabilities, 2017, 30, 416-418.	1.3	45
14	Elucidating the diagnostic odyssey of 22q11.2 deletion syndrome. American Journal of Medical Genetics, Part A, 2018, 176, 936-944.	0.7	45
15	All-cause mortality and survival in adults with 22q11.2 deletion syndrome. Genetics in Medicine, 2019, 21, 2328-2335.	1.1	44
16	Coâ€occurrence of earlyâ€onset Parkinson disease and 22q11.2 deletion syndrome: Potential role for dopamine transporter imaging. American Journal of Medical Genetics, Part A, 2010, 152A, 2937-2938.	0.7	43
17	Neuroimaging and clinical features in adults with a 22q11.2 deletion at risk of Parkinsonâ€™s disease. Brain, 2017, 140, 1371-1383.	3.7	41
18	AMPT-induced monoamine depletion in humans: evaluation of two alternative [123I]IBZM SPECT procedures. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1350-1356.	3.3	38

#	Article	IF	Citations
19	White matter abnormalities in adults with 22q11 deletion syndrome with and without schizophrenia. Schizophrenia Research, 2011, 132, 75-83.	1.1	37
20	Proton Magnetic Resonance Spectroscopy in 22q11 Deletion Syndrome. PLoS ONE, 2011, 6, e21685.	1.1	37
21	Systematic Review of N-of-1 Studies in Rare Genetic Neurodevelopmental Disorders. Neurology, 2021, 96, 529-540.	1.5	36
22	Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11.2. Neurology, 2018, 90, e2059-e2067.	1.5	35
23	A mouse model of 22q11.2 deletions: Molecular and behavioral signatures of Parkinsonâ€™s disease and schizophrenia. Science Advances, 2018, 4, eaar6637.	4.7	35
24	Massive increase in serum creatine kinase during olanzapine and quetiapine treatment, not during treatment with clozapine. Psychopharmacology, 2000, 150, 347-348.	1.5	30
25	A genetic model for multimorbidity in young adults. Genetics in Medicine, 2020, 22, 132-141.	1.1	29
26	Dopamine metabolism in adults with 22q11 deletion syndrome, with and without schizophrenia â€“ relationship with COMT Val^{108/158} Met polymorphism, gender and symptomatology. Journal of Psychopharmacology, 2011, 25, 888-895.	2.0	28
27	Functional Gene-Expression Analysis Shows Involvement of Schizophrenia-Relevant Pathways in Patients with 22q11 Deletion Syndrome. PLoS ONE, 2012, 7, e33473.	1.1	27
28	Neuropsychiatric expression and catatonia in 22q11.2 deletion syndrome: An overview and case series. American Journal of Medical Genetics, Part A, 2018, 176, 2146-2159.	0.7	25
29	Cortical Morphology Differences in Subjects at Increased Vulnerability for Developing a Psychotic Disorder: A Comparison between Subjects with Ultra-High Risk and 22q11.2 Deletion Syndrome. PLoS ONE, 2016, 11, e0159928.	1.1	23
30	22q11.2 Deletion Syndromeâ€“Associated Parkinson's Disease. Movement Disorders Clinical Practice, 2019, 6, 11-16.	0.8	22
31	Striatal D2receptor binding in 22q11 deletion syndrome: an [123 I]IBZM SPECT study. Journal of Psychopharmacology, 2010, 24, 1525-1531.	2.0	20
32	COMT Val¹⁵⁸met genotype and striatal D_{2/3} receptor binding in adults with 22q11 deletion syndrome. Synapse, 2011, 65, 967-970.	0.6	17
33	Serotonergic, noradrenergic and dopaminergic markers are related to cognitive function in adults with 22q11 deletion syndrome. International Journal of Neuropsychopharmacology, 2014, 17, 1159-1165.	1.0	17
34	22q11.2 microdeletion and increased risk for type 2 diabetes. EClinicalMedicine, 2020, 26, 100528.	3.2	15
35	Pericardial and bilateral pleural effusion associated with clozapine treatment. European Psychiatry, 2004, 19, 65-65.	0.1	14
36	Startle reactivity and prepulse inhibition of the acoustic startle response are modulated by catechol-O-methyl-transferase Val¹⁵⁸ Met polymorphism in adults with 22q11 deletion syndrome. Journal of Psychopharmacology, 2012, 26, 1548-1560.	2.0	14

#	Article	IF	Citations
37	Parkinsonism in Phenylketonuria: A Consequence of Dopamine Depletion?. JIMD Reports, 2014, 20, 35-38.	0.7	14
38	Low prevalence of substance use in people with 22q11.2 deletion syndrome. British Journal of Psychiatry, 2019, 215, 661-667.	1.7	13
39	Nonâ€pharmacological treatment of psychiatric disorders in individuals with 22q11.2 deletion syndrome; a systematic review. American Journal of Medical Genetics, Part A, 2018, 176, 1742-1747.	0.7	12
40	Adverse effects of antipsychotic medication in patients with 22q11.2 deletion syndrome: A systematic review. American Journal of Medical Genetics, Part A, 2019, 179, 2292-2306.	0.7	12
41	PRODH rs450046 and proline x COMT Val158Met interaction effects on intelligence and startle in adults with 22q11 deletion syndrome. Psychopharmacology, 2015, 232, 3111-3122.	1.5	11
42	Possible underreporting of pathogenic variants in <scp>RAI1</scp> causing <scp>Smithâ€“Magenis</scp> syndrome. American Journal of Medical Genetics, Part A, 2021, 185, 3167-3169.	0.7	10
43	Functional Analysis of Novel Genetic Variation in the Thyroid Hormone Activating Type 2 Deiodinase. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2429-E2436.	1.8	8
44	Overexpression of Chromosome 15q11-q13 Gene Products: A Risk Factor for Schizophrenia and Associated Psychoses?. American Journal of Psychiatry, 2012, 169, 96-97.	4.0	6
45	Dopamine in high-risk populations: A comparison of subjects with 22q11.2 deletion syndrome and subjects at ultra high-risk for psychosis. Psychiatry Research - Neuroimaging, 2018, 272, 65-70.	0.9	6
46	Rare copy number variations affecting the synaptic gene DMXL2 in neurodevelopmental disorders. Journal of Neurodevelopmental Disorders, 2019, 11, 3.	1.5	6
47	Ocular findings in 22q11.2 deletion syndrome: A systematic literature review and results of a Dutch multicenter study. American Journal of Medical Genetics, Part A, 2022, 188, 569-578.	0.7	6
48	Cognitive behavioral therapy in 22q11.2 deletion syndrome: A case study of two young adults with an anxiety disorder. Journal of Intellectual Disabilities, 2021, 25, 695-704.	1.0	5
49	<scp>Ageâ€Related</scp> Parkinsonian Signs in Microdeletion 22q11.2. Movement Disorders, 2020, 35, 1239-1245.	2.2	4
50	Sexual knowledge and behaviour in 22q11.2 deletion syndrome, a complex care condition. Journal of Applied Research in Intellectual Disabilities, 2022, 35, 966-975.	1.3	4
51	Personalized medical information card for adults with 22q11.2 deletion syndrome: An initiative to improve communication between patients and healthcare providers. Journal of Applied Research in Intellectual Disabilities, 2020, 33, 1534-1540.	1.3	2
52	Unexpected Detection of Nodular Melanoma of the Skin on the Scalp by I-123 IBZM Brain SPECT. Clinical Nuclear Medicine, 2011, 36, 148-149.	0.7	1
53	Enhanced Maternal Origin of the 22q11.2 Deletion in Velocardiofacial and DiGeorge Syndromes. American Journal of Human Genetics, 2013, 92, 637.	2.6	1
54	Cardiac sympathetic activity in 22q11.2 deletion syndrome. International Journal of Cardiology, 2016, 212, 346-351.	0.8	1

#	Article	IF	Citations
55	Post-traumatic stress in adults with 22q11.2 deletion syndrome. BJPsych Open, 2022, 8, .	0.3	1
56	Poster #106 STARTLE REACTIVITY AND PREPULSE INHIBITION OF THE ACOUSTIC STARTLE RESPONSE ARE MODULATED BY COMT VAL MET POLYMORPHISM IN ADULTS WITH 22Q11 DELETION SYNDROME. Schizophrenia Research, 2012, 136, S223-S224.	1.1	0
57	F207. Neurocognition and Adaptive Functioning in the 22q11.2 Deletion Syndrome Model of Schizophrenia. Biological Psychiatry, 2018, 83, S319.	0.7	0
58	Elevated regional cerebral blood flow in adults with 22q11.2 deletion syndrome. World Journal of Biological Psychiatry, 2023, 24, 260-265.	1.3	0